Merrill maintains MGI at buy

MGI Pharma Inc. was maintained by Merrill Lynch analyst Eric Ende at a buy rating after the company preannounced fourth-quarter Aloxi sales of $67 million, which suggest 5% sequential growth. The company also provided 2006 Aloxi guidance of $285 million to $300 million, which is in line with Merrill's conservative $288 million estimate. Merrill said it expects Dacogen approval in the second quarter of 2006 to help maintain growth. Shares of the Bloomington, Minn., pharmaceutical company were down 99 cents, or 5.51%, at $16.99 on volume of 8,574,301 shares versus the three-month running average of 1,403,540 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.